Relapsed childhood acute lymphoblastic leukaemia

Area of Science:

• Pediatric Oncology
• Hematology
• Cancer Biology

Background:

• Cure rates for newly diagnosed acute lymphoblastic leukaemia (ALL) in children have improved.
• Relapsed ALL presents significant treatment challenges, primarily due to resistance to salvage therapies.

Purpose of the Study:

• To outline the necessary advancements for improving outcomes in relapsed ALL.
• To highlight promising therapeutic strategies and supportive care improvements.

Main Methods:

• Review of current challenges in relapsed ALL treatment.
• Identification of key areas for biological and therapeutic advancement.
• Discussion of innovative treatment modalities and supportive care.

Main Results:

• Understanding relapse mechanisms and drug resistance is crucial.
• Actionable molecular targets can be identified through genetic studies.
• Minimum residual disease measurement aids in risk stratification.

Conclusions:

• Molecularly targeted therapies and immunotherapies offer potential for enhanced leukaemia cell killing.
• Advances in haemopoietic stem-cell transplantation can improve success rates for high-risk patients.
• Integrated approaches combining biological insights, targeted therapies, and improved transplantation are essential for better relapsed ALL outcomes.